GLP‑1 treatment in Nebraska
Who ships GLP-1 medication to Nebraska, what Medicaid covers, and the telehealth rules that apply.
What the federal data shows for Nebraska
1,806 clinicians in Nebraska prescribed Ozempic to Medicare Part D patients in 2024, across 59,231 claims. That is the most-prescribed GLP-1 in the state by prescriber count. Part D covers Medicare only, so the figure is a floor on prescribing in Nebraska rather than a total.
Nebraska Medicaid reimbursed $9,426,205.73 for 9,278 GLP-1 prescriptions in Q1 2026, or $1,015.97 per prescription. From CMS State Drug Utilization, fee-for-service and managed care combined. Suppressed cells are excluded, never counted as zero.
1 outsourcing facilities registered with the FDA under section 503B give a Nebraska address, and 0 of them have no recorded FDA inspection. Registration is a filing, not an approval, and an uninspected facility has not passed an inspection — it has not had one. Each one has a page in the 503B register.
What is on this page
- 7 drug cost pages for Nebraska, each pairing the state's Medicaid figures with pharmacy acquisition cost
- 2 city pages showing where GLP-1 prescribers practise in Nebraska
- Every link below is a page for Nebraska specifically, not a national page filtered to it
- CMS NADACNational Average Drug Acquisition Cost, weekly file
- CMS Medicare Part DPrescriber public use file, by geography and drug
- CMS State Drug UtilizationQuarterly Medicaid prescription and reimbursement data
NADAC figures are pharmacy acquisition costs, not retail prices and not what you will pay. This content is educational and is not medical advice.